文献速递青光眼

微脉冲经巩膜睫状体光凝对青光眼及高眼压症患者房水动力学的影响

Effect of micropulse trans-scleral cyclophotocoagulation (MP-TSCPC) on aqueous humour dynamics in patients with glaucoma and ocular hypertension: an observational study.
PubMed 文献 · Br J Ophthalmol · 2026-04-09

这项观察性研究评估了微脉冲经巩膜睫状体光凝(MP-TSCPC)对开角型青光眼和高眼压症患者房水动力学的影响。31例患者中28例完成6个月随访,平均眼压显著下降10%,房水生成显著减少26.08%,但房水流出易度和葡萄膜巩膜流出无统计学显著变化。结论认为MP-TSCPC主要通过减少房水生成降低眼压,对流出通路无明显影响。

要点

  • MP-TSCPC术后6个月平均眼压从25.08±5.06 mmHg降至22.56±4.89 mmHg,降幅10%,p=0.005。
  • 房水生成从2.34±0.64降至1.74±0.4 µL/min,降幅26.08%,p=0.0001。
  • 房水流出易度和葡萄膜巩膜流出无统计学显著变化。

核心结论

  • MP-TSCPC主要通过减少房水生成来降低眼压,对流出通路无明显影响。
  • MP-TSCPC被认为是青光眼和高眼压症安全有效的治疗选择。

研究设计与样本

  • 观察性研究,纳入31例接受MP-TSCPC的开角型青光眼和高眼压症患者,其中28例完成6个月随访。
  • 患者中61%为男性,71%为黑人种族。

主要发现

  • 平均眼压从25.08±5.06 mmHg降至22.56±4.89 mmHg,显著降低10%(p=0.005)。
  • 房水生成从2.34±0.64降至1.74±0.4 µL/min,显著降低26.08%(p=0.0001)。
  • 房水流出易度和葡萄膜巩膜流出无统计学显著变化。
  • 治疗耐受良好,报告的不良事件轻微且少见。

临床怎么用

  • MP-TSCPC可用于开角型青光眼和高眼压症的降眼压治疗,机制以抑制房水生成为主。
  • 术后应关注眼压和房水生成的变化,而非预期流出通路的改善。

局限性

  • 研究为观察性设计,样本量较小(31例入组,28例完成随访)。
  • 随访时间仅6个月,长期疗效和机制尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glaucoma, a leading cause of irreversible blindness worldwide, affects over 60 million people globally and 700 000 in the UK. Elevated intraocular pressure (IOP) is the only modifiable risk factor for disease progression. Micropulse trans-scleral cyclophotocoagulation (MP-TSCPC) offers a promising alternative to conventional treatments by reducing IOP with minimal complications. Although MP-TSCPC is hypothesised to lower IOP by decreasing aqueous humour production and altering aqueous outflow, the precise mechanisms remain poorly understood. AIMS: This study aimed to evaluate the effects of MP-TSCPC on aqueous humour dynamics in patients with open-angle glaucoma and ocular hypertension (OHT), focusing on IOP, aqueous humour production and outflow pathways 6 months post treatment. RESULTS: Of the 31 patients undergoing MP-TSCPC, 61% were men, of which 71% were of black ethnicity, with 28 patients completing the 6-month follow-up. A significant 10% reduction in mean IOP (25.08±5.06 mm Hg to 22.56±4.89 mm Hg, p=0.005) and a 26.08% reduction in aqueous humour production (from 2.34±0.64 to 1.74±0.4 µL/min, p=0.0001) were observed. There were no statistically significant changes in tonographic outflow facility or uveoscleral outflow. Treatment was well-tolerated, with few mild adverse events reported. CONCLUSION: This study demonstrates that MP-TSCPC reduces IOP primarily through decreased aqueous humour production, with no discernible impact on outflow pathways. These findings refine the understanding of MP-TSCPC's mechanism of action, highlighting its potential as a safe and effective treatment for glaucoma and OHT. Future studies should explore ways to enhance efficacy and long-term outcomes.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Daas A, Patel B, Ranjit A, et al. Effect of micropulse trans-scleral cyclophotocoagulation (MP-TSCPC) on aqueous humour dynamics in patients with glaucoma and ocular hypertension: an observational study. Br J Ophthalmol. 2026. PMID: 41956740. doi:10.1136/bjo-2025-327787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。